Carasent AB (publ) (STO:CARA)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 1.63B |
| Revenue (ttm) | 349.05M |
| Net Income (ttm) | 40.61M |
| Shares Out | 68.47M |
| EPS (ttm) | 0.59 |
| PE Ratio | 40.47 |
| Forward PE | 33.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,817 |
| Average Volume | 154,945 |
| Open | 23.75 |
| Previous Close | 23.80 |
| Day's Range | 23.10 - 23.85 |
| 52-Week Range | 21.85 - 31.25 |
| Beta | 0.28 |
| RSI | 49.04 |
| Earnings Date | Apr 14, 2026 |
About Carasent AB
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden. [Read more]
Financial Performance
Financial StatementsNews
Carasent AB Earnings Call Transcript: Q1 2026
ARR grew 16% year-over-year with strong profitability and 19% growth in the Nordics, while German revenues declined due to legacy churn. AI-driven product enhancements and Medsum adoption are key growth drivers, with share buybacks and targeted acquisitions planned.
Carasent AB Earnings Call Transcript: Q4 2025
Q4 saw 15% organic ARR growth, a 16% EBITDA margin, and strong profitability, driven by major client migrations and high consulting revenues. AI investments continue, with Medsom now using OpenAI, and the sales pipeline remains robust, especially in the Nordics.
Carasent AB Earnings Call Transcript: Q3 2025
Q3 saw 16% organic ARR growth, 29% EBITDA margin, and strong cost control, with major product rollouts in Germany and Scandinavia. Revenue timing in Q4 depends on key project implementations, while SEK 70 million was spent on share buybacks, leaving a SEK 170 million cash balance.
Carasent AB Earnings Call Transcript: Q2 2025
Revised targets reflect project delays, restructuring, and increased AI investment, but ARR and recurring revenue continue to grow. Key wins in Västra Götaland and strong AI product development support a positive outlook, though execution risks remain.
Carasent AB Earnings Call Transcript: Q1 2025
EBITDA margin turned positive to 6% and revenue grew 29% year-over-year, driven by strong organic and acquired growth. AI investments and receivable write-downs slightly increased costs, but cash flow and ARR remain robust. Focus continues on growth, efficiency, and targeted M&A.
Carasent AB Earnings Call Transcript: Q4 2024
Q4 saw strong ARR and margin growth, driven by the Data-Al acquisition and cost efficiencies. One-off costs impacted EBITDA, but underlying profitability and cash flow remain robust. Outlook is positive, with key projects and market changes expected to fuel growth in 2024-2025.
Carasent AB Transcript: M&A Announcement
The acquisition of Data-AL enables immediate entry into Germany's large, fragmented EHR market, leveraging local expertise and a stable customer base. The deal is expected to drive revenue growth through cloud migration, with integration and commercial rollout of Webdoc X planned over the next few years.
Carasent AB Earnings Call Transcript: Q3 2024
Q3 saw strong organic growth, improved EBITDA, and higher gross margins, with robust contract wins and a positive outlook for continued expansion. One-time costs from relisting and acquisitions impacted results, but cost control and efficiency measures are driving profitability.
Carasent AB Earnings Call Transcript: Q2 2024
Delivered 15% recurring revenue growth and improved margins, with major new contracts signed and strong cost control. Relisting to Nasdaq Stockholm and product launches position the company for accelerated growth and profitability in the coming year.